SEC Form SC 13D/A filed by ANI Pharmaceuticals Inc. (Amendment)

$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ANIP alert in real time by email
SC 13D/A 1 tm2232474d1_sc13da.htm SC 13D/A

 

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, DC 20549

 

SCHEDULE 13D/A

 

(Amendment No. 5)

 

Under the Securities Exchange Act of 1934

 

ANI Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

 

00182C103

(CUSIP Number)

 

Robert A. Graham

MVP Capital Partners

259 N. Radnor-Chester Road

Suite 130, Radnor, PA  19087

Tel:  (610) 254-2999

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

December 1, 2022

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 00182C103 13D
   

 

1.

Name of Reporting Persons

 

Meridian Venture Partners II GP, L.P. (“GP”)

 

 
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a) ¨
     
  (b) x (1)
     
 
3.

SEC Use Only

 

 

 
4.

Source of Funds (See Instructions)

 

OO

 

 
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
   
 
6.

Citizenship or Place of Organization

 

Delaware, United States of America

 

 

 

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0 shares

 

 
8.

Shared Voting Power

 

2,019,259 shares of Common Stock

 

 
9.

Sole Dispositive Power

 

0 shares

 

 
10.

Shared Dispositive Power

 

2,019,259 shares of Common Stock

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,019,259 shares of Common Stock

 

 
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
   
 
13.

Percent of Class Represented by Amount in Row 11

 

11.6% (2)

 

 
14.

Type of Reporting Person (See Instructions)

 

PN

 

 

 

 

(1) This statement on Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

 

(2) Percentage is based on 17,453,805 shares of the Company’s Common Stock, par value $0.0001 per share, outstanding as of November 2, 2022, as reported on the Company’s Form 10-Q for the period ended September 30, 2022.

 

 

 

 

CUSIP No. 00182C103 13D
   

 

1.

Name of Reporting Persons

 

Meridian Venture Partners II, L.P. (“MVP II”),

 

 
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a) ¨
     
  (b) x  (1)
     
 
3.

SEC Use Only

 

 

 
4.

Source of Funds (See Instructions)

 

OO

 

 
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
   
 
6.

Citizenship or Place of Organization

 

Delaware

 

 

 

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0 Shares

 

 
8.

Shared Voting Power

 

2,019,259 shares of Common Stock

 

 
9.

Sole Dispositive Power

 

0 Shares

 

 
10.

Shared Dispositive Power

 

2,019,259 shares of Common Stock

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,019,259 shares of Common Stock

 

 
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
   
 
13.

Percent of Class Represented by Amount in Row 11

 

11.6% (2)

 

 
14.

Type of Reporting Person (See Instructions)

 

PN

 

 

 

 

(1) This statement on Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

 

(2) Percentage is based on 17,453,805 shares of the Company’s Common Stock, par value $0.0001 per share, outstanding as of November 2, 2022, as reported on the Company’s Form 10-Q for the period ended September 30, 2022.

 

 

 

 

CUSIP No. 00182C103

13D

   

 

1.

Name of Reporting Persons

 

Meridian Venture Partners II, Co. (“MVP Corp.”)

 

 
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a) ¨
     
  (b) x (1)
     
 
3.

SEC Use Only

 

 

 
4.

Source of Funds (See Instructions)

 

OO

 

 
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
   
 
6.

Citizenship or Place of Organization

 

Delaware

 

 

 

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0 shares

 

 
8.

Shared Voting Power

 

2,019,259 shares of Common Stock

 

 
9.

Sole Dispositive Power

 

0 shares

 

 
10.

Shared Dispositive Power

 

2,019,259 shares of Common Stock

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,019,259 shares of Common Stock

 

 
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
   
 
13.

Percent of Class Represented by Amount in Row 11

 

11.6% (2)

 

 
14.

Type of Reporting Person (See Instructions)

 

CO

 

 

 

 

(1) This statement on Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

 

(2) Percentage is based on 17,453,805 shares of the Company’s Common Stock, par value $0.0001 per share, outstanding as of November 2, 2022, as reported on the Company’s Form 10-Q for the period ended September 30, 2022.

 

 

 

 

CUSIP No. 00182C103 13D
   

 

1.

Name of Reporting Persons

 

Robert E. Brown, Jr.

 

 
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a) ¨
     
  (b) x  (1)
     
 
3.

SEC Use Only

 

 

 
4.

Source of Funds (See Instructions)

 

OO

 

 
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
   
 
6.

Citizenship or Place of Organization

 

United States of America

 

 

 

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

49,021 Shares

 

 
8.

Shared Voting Power

 

2,019,259 shares of Common Stock

 

 
9.

Sole Dispositive Power

 

49,021 Shares

 

 
10.

Shared Dispositive Power

 

2,019,259 shares of Common Stock

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,068,280 shares of Common Stock

 

 
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
   
 
13.

Percent of Class Represented by Amount in Row 11

 

11.8% (2)

 

 
14.

Type of Reporting Person (See Instructions)

 

IN

 

 

 

 

(1) This statement on Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

 

(2) Percentage is based on 17,453,805 shares of the Company’s Common Stock, par value $0.0001 per share, outstanding as of November 2, 2022, as reported on the Company’s Form 10-Q for the period ended September 30, 2022.

 

 

 

 

Item 1. Security and Issuer.

 

This Amendment No. 5 on Schedule 13D (this “Schedule 13D”) relates to ANI Pharmaceuticals, Inc.'s (the “Company”) common stock, $0.0001 par value (the “Common Stock”) and amends and further supplements the Schedule 13D originally filed on July 1, 2013 (as amended from time to time, the “Statement”) by Meridian Venture Partners II GP, L.P., a limited partnership organized under the laws of the State of Delaware (“GP”), Meridian Venture Partners II, L.P., a limited partnership organized under the laws of State of Delaware (“MVP II”), Meridian Venture Partners II, Co., a Delaware corporation (“MVP Corp.”) and Mr. Robert E. Brown, Jr. (collectively with GP, MVP II, and MVP Corp., the “Reporting Persons”). The Reporting Persons are filing this Schedule 13D to report the sale by the Reporting Persons of 200,000 shares of Common Stock on December 1, 2022. Except as expressly set forth herein, there have been no changes to the Statement. The Company’s principal executive offices are located at 210 Main Street West, Baudette, Minnesota 56623.

 

Item 4. Purpose of Transaction.

 

The shares of Common Stock owned by the Reporting Persons were acquired solely for investment purposes.

 

On December 1, 2022, the Reporting Persons sold 200,000 shares of Common Stock for its liquidity purposes, and no additional sales are planned at this time.

 

Item 5. Interest in Securities of the Issuer.

 

(a) and (b) Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person.  Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person.  Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person.  Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person.  Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person.  Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person.

 

(c) During the past sixty days the Reporting Persons sold 200,000 shares of Common Stock at a price per share of $38.50. The Reporting Persons will provide to the Securities Exchange Commission complete information regarding each of these transactions upon request.

 

  (d) Not applicable

 

  (e) Not applicable

 

 

 

 

SIGNATURES

 

After reasonable inquiry and to the best of the undersigned knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

December 12, 2022 Meridian Venture Partners II GP, L.P.
     
  BY: Meridian Venture Partners II, Co.
     
  ITS: GENERAL PARTNER
     
  By: /s/ Robert E. Brown, Jr.
     
    Robert E. Brown, Jr., President

 

December 12, 2022 Meridian Venture Partners II, L.P.
   
  BY: Meridian Venture Partners II GP, L.P.
     
  ITS: GENERAL PARTNER
     
    BY: Meridian Venture Partners II, Co.
     
    ITS: GENERAL PARTNER
     
  By: /s/ Robert E. Brown, Jr.
     
    Robert E. Brown, Jr., President

 

 

 

 

December 12, 2022 Meridian Venture Partners II, Co.
     
  By: /s/ Robert E. Brown, Jr.
     
    Robert E. Brown, Jr., President

 

December 12, 2022 ROBERT E. BROWN, JR.
     
  By: /s/ Robert E. Brown, Jr.
     
    Robert E. Brown, Jr.

 

 

 

Get the next $ANIP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANIP

DatePrice TargetRatingAnalyst
12/11/2024$80.00Outperform
Leerink Partners
10/11/2024$68.00Overweight
Piper Sandler
3/15/2024$80.00Overweight
CapitalOne
8/22/2023$60.00 → $73.00Buy
H.C. Wainwright
3/1/2023$55.00Buy
Guggenheim
9/7/2022$50.00Buy
H.C. Wainwright
11/2/2021$60.00 → $65.00Outperform
Raymond James
11/2/2021$70.00Buy
Truist
More analyst ratings

$ANIP
Press Releases

Fastest customizable press release news feed in the world

See more
  • ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March

    PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates' 46th Annual Institutional Investors ConferenceTuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare ConferenceTuesday, March 11, 2025, at 3:40pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be acce

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

    PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, February 28, 2025  Time8:00 a.m. ET  Toll free (U.S.) 800-579-2543  Conference ID4860276  Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section  

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

    PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows:   Date:Wednesday, February 5, 2025Time:2:00pm ESTWebcast:Click here   The live and archived webcast will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 60 days. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) i

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANIP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ANIP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANIP
SEC Filings

See more

$ANIP
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

    Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for OXYCODONE AND ASPIRIN

    Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for EZETIMIBE AND SIMVASTATIN

    Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANIP
Leadership Updates

Live Leadership Updates

See more
  • Alcami Announces CEO Transition

    Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries  DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

    -- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

    ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANIP
Financials

Live finance-specific insights

See more
  • ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

    PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, February 28, 2025  Time8:00 a.m. ET  Toll free (U.S.) 800-579-2543  Conference ID4860276  Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section  

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

    For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024Rare Disease Segment performed in line with expectations, with Purified Cortrophin Gel net revenues of $197.8 million to $198.4 million for the full year 2024 and ILUVIEN and YUTIQ net revenues of $30.4 million to $31.0 million for the post-acquisition period from September 16, 2024 to December 31, 2024, based on preliminary, unaudited resultsEstablished preliminary financial outlook for 2025, including total net revenues of $739 million to $759 million and adjusted non-GAAP EBITDA of $182 million to $192 mil

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

    Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-yearNet loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 millionDiluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioImplemented new capital structure that is expected to reduce interest expense by approximately $39.0 million on an annualized basis (1)Inc

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANIP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more